Tech Company Financing Transactions
resTORbio Funding Round
resTORbio, based in Boston, secured $40 million from OrbiMed, Fidelity Management & Research Company and Nest.Bio Ventures.
Transaction Overview
Company Name
Announced On
12/1/2017
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series B
Investors
OrbiMed (Lead Investor) (Jonathan Silverstein)
Proceeds Purpose
resTORbio plans to use the proceeds to advance the development of RTB101, a selective Target of Rapamycin Complex 1 (TORC1) inhibitor through Phase 2b clinical trial and, if successful, into a Phase 3 clinical program, as an immunotherapy to reduce the incidence of respiratory tract infections (RTIs) in elderly subjects. The funds are also expected to be used to expand the program into a Phase 2 clinical trial in an additional aging-related indication.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
500 Boylston St. 12th Floor
Boston, MA 02116
USA
Boston, MA 02116
USA
Phone
Website
Email Address
Overview
resTORbio, Inc. is a clinical stage company, developing medicines to treat aging-related diseases and conditions. resTORbio's lead program targets the mechanistic target of rapamycin complex 1 (mTORC1) pathway to treat aging-related diseases and conditions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Chen Schor
Chief Medical Officer
Joan Mannick
VP - Finance
John McCabe
VP - Operations
Sarb Shergill
VP - Regulatory Affairs
Karen Jauregui
Browse more venture capital transactions:
Prev: 11/30/2017: Mavupharma venture capital transaction
Next: 12/1/2017: NanoCellect Biomedical venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record every notable VC transaction. VC transactions reported here come from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs